Iran Reportedly Offers Plan to Open Strait | The China Show 4/27/2022

Watch on YouTube ↗  |  April 27, 2026 at 06:40  |  1:32:34  |  Bloomberg Markets
Speakers
Rebecca Liang — Reporter, The Block
David Savage — Editor, The Block

Summary

The China Show covers breaking news that Iran offered a new proposal to reopen the Strait of Hormuz, sparking a drop in oil and a rally in Asian equities. The show previews a massive earnings week in Asia and globally, with focus on tech and AI stocks. Segments discuss fixed income positioning, China's growing dominance in pharmaceuticals, and the implications of DeepSeek's new AI model for chip self-sufficiency.

  • Iran reportedly offers a plan to reopen the Strait of Hormuz via Pakistani mediators, leading to a rapid decline in Brent crude oil prices.
  • Asian equities rise on the news, with tech-heavy indices like Taiwan and South Korea leading gains.
  • A busy earnings week features over 400 MSCI Asia Pacific members reporting, including Samsung, BYD, and major US tech firms.
  • All G-7 central banks meet this week, expected to maintain rates but with hawkish rhetoric on inflation.
  • Fixed income strategist Rachana Mehta favors buying 5-6 year bonds for carry and would add long duration on 30-year US Treasuries above 5.1%.
  • Bernstein analyst Rebecca Liang highlights Innovent Biologics and Hengrui Medicine as top picks in China's maturing pharmaceutical sector.
  • Bloomberg Intelligence notes DeepSeek's V4 model is heavily reliant on Huawei chips, underscoring China's push for semiconductor self-sufficiency.
  • The show discusses inequality in equity markets, with fewer than 5% of global stocks at 52-week highs despite record benchmarks.
Trade Ideas
Rachana Mehta 13:51
Bullish bonds, add duration on yield break.
She is positive on bonds, expecting 5-6% return from carry on 5-6 year bonds this year. She prefers a flat trade (long duration) because if central banks stay hawkish, investors will buy the long end, and she would add long duration on 30-year US Treasury if yields break above 5.1-5.2%, as she believes those levels offer medium-term value.
5-6 year bonds 30-year U.S. Treasury MED
Rebecca Liang Reporter, The Block 77:28
Long Innovent Biologics and Hengrui Medicine.
She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.
Innovent Biologics 600276.SS HIGH
Up Next
46:33
Hormuz Blockade, AI Race and Asia’s Great Market Divide | Insight with Haslinda Amin 04/27/2026
Bloomberg Markets · Apr 27
3:34
What We Know About the Gunman in DC Gala Attack
Bloomberg Markets · Apr 27
3:09
Fed, BOJ, Bank of Canada Expected to Hold Rates
Bloomberg Markets · Apr 27
1:35:14
Markets on Edge With Rates, Earnings, Iran in Focus | The Asia Trade 4/27/2026
Bloomberg Markets · Apr 27
7:55
How SEAL 911 and Arbitrum Froze $70M of North Korea's Stolen Funds
Unchained (Chopping Block) · Apr 26

This Bloomberg Markets video, published April 27, 2026, features Rachana Mehta, Rebecca Liang discussing 5-6 year bonds, 30-year U.S. Treasury, Innovent Biologics, 600276.SS. 2 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Rachana Mehta, Rebecca Liang  · Tickers: 5-6 year bonds, 30-year U.S. Treasury, Innovent Biologics, 600276.SS